Effect of platelet indices on postoperative pain and edema in bimaxillary surgery.

OBJECTIVES: To investigate the influence of platelet volume indices (PVI) on postoperative pain and edema in patients undergoing bimaxillary surgery and assessed the associations between PVI parameters and other clinical factors. METHODS: We examined the medical records of 50 patients aged 18-40, treated between 2019 and 2020. Platelet indices (platelet count [PLT]), mean platelet volume, platelet distribution width, plateletcrit (PCT), and platelet large cell ratio) were analyzed. Postoperative pain and edema were assessed based on the frequency of intravenous (IV) analgesic administration and 3D imaging. A lasso-penalized regression was used for the analysis. RESULTS: Significant positive correlations were observed between PLT and postoperative edema on the first (T1-0) and third (T3-0) postoperative days. Furthermore, PLT was positively associated with the number of IV analgesic drug administrations from 24 to 72 hours after surgery. Additionally, a discernible positive correlation was identified between PCT levels and the quantity of IV analgesic drugs administered within the first 24 hours after surgery. CONCLUSION: Platelet indices, particularly PLT and PCT levels, were associated with postoperative pain and edema in patients undergoing bimaxillary surgery. These indices have the potential to serve as biomarkers for predicting and managing postoperative complications of orthognathic surgery. Further studies are required to explore the clinical utility and implications of these findings.

Molecular cloning of the OMP19 gene from Brucella melitensis strain H38 and its antigenicity compared to that of commercial OMP19.

Brucellosis is a worldwide zoonosis, that can still be classified as endemic despite its ancient origins which causes economic losses and public health problems. Although effectively controlled by vaccination in animals, there is currently no vaccine for use in humans. Outer Membrane Proteins (OMP) that play an active immunogenic and protective role in the Brucellae family. OMP19 is present in all Brucella species as a surface antigen and is a potent immunogen responsible for Brucellosis intracellular infection. For this reason, the study was aimed to be used safely as a potential recombinant vaccine candidate against all Brucella infections, especially in humans and pregnant animals. This study evaluated a Brucella lipoprotein antigen, i.e. 19 kilodalton (kDa) outer membrane protein (OMP19), which was amplified and cloned into the pETSUMO vector system. The immunogenic power of the purified recombinant OMP19 antigen against brucellosis was compared with that of OMP19 (Raybiotech Inc, USA) in a mouse model and the obtained rOMP19 antigen was found to be similar to the commercially available recombinant protein.